title: Alpha-1 adrenergic receptor binding and adrenergic-stimulated cyclic AMP production in rat cerebral cortex after chronic lithium treatment.
abstract: Administration to rats of dietary lithium for 30 days was followed by evaluation of alpha-1 adrenergic receptor binding and of adrenergic-stimulated cyclic AMP (cAMP) accumulation in rat cerebral cortex. Chronic lithium treatment did not alter the binding characteristics of [3H]prazosin or the proportion of alpha-1 adrenergic receptor subtypes distinguished by chlorethyl-clonidine (CEC) pretreatment in rat cerebral cortical membranes. Accumulation of cAMP in cortical slices incubated with adrenergic agonists was unaffected in lithium-treated rats. These results demonstrate that chronic lithium treatment-induced reduction of norepinephrine (NE)-stimulated phosphoinositide (PI) hydrolysis (Casebolt and Jope, 1987) is not due to changes in the alpha-1 adrenergic receptor and is more sensitive to in vivo lithium treatment than is adrenergic-stimulated cAMP accumulation.
authors.affiliation: Department of Psychiatry, University of Alabama, Birmingham.
authors.forename: T L
authors.initials: TL
authors.lastname: Casebolt
authors.forename: X H
authors.initials: XH
authors.lastname: Li
authors.forename: R S
authors.initials: RS
authors.lastname: Jope
mesh_terms: D000284:Administration, Oral; D000316:Adrenergic alpha-Agonists / Q000378:metabolism*; D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism; D002712:Chlorides / Q000008:administration & dosage / Q000494:pharmacology*; D003000:Clonidine / Q000031:analogs & derivatives / Q000494:pharmacology; D000242:Cyclic AMP / Q000096:biosynthesis*; D008094:Lithium / Q000008:administration & dosage / Q000494:pharmacology*; D018021:Lithium Chloride; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism; D011224:Prazosin / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000145:classification / Q000187:drug effects* / Q000378:metabolism; D015290:Second Messenger Systems / Q000187:drug effects
chemical_list: D000316:Adrenergic alpha-Agonists; D002712:Chlorides; D010716:Phosphatidylinositols; D011942:Receptors, Adrenergic, alpha; C051731:chlorethylclonidine; D008094:Lithium; D000242:Cyclic AMP; D018021:Lithium Chloride; D003000:Clonidine; D009638:Norepinephrine; D011224:Prazosin